These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38612621)

  • 61. Longitudinal Assessment of Timed Function Tests in Ambulatory Individuals with SMA Treated with Nusinersen.
    Krosschell KJ; Brown L; Hoffman K; Zumpf KB; Munson H; Bidwell J; Schulte DP; Schwaede AN; Buehner AN; DiDonato CJ; Kuntz NL; Rao VK
    J Neuromuscul Dis; 2023; 10(3):337-348. PubMed ID: 36872785
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
    Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
    Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.
    Chacko A; Sly PD; Ware RS; Begum N; Deegan S; Thomas N; Gauld LM
    Thorax; 2022 Jan; 77(1):40-46. PubMed ID: 33963091
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
    Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
    Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
    Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
    Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 68. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters.
    Stolte B; Nonnemacher M; Kizina K; Bolz S; Totzeck A; Thimm A; Wagner B; Deuschl C; Kleinschnitz C; Hagenacker T
    J Neurol; 2021 Dec; 268(12):4667-4679. PubMed ID: 33899154
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impaired diaphragmatic motility in treatment-naive adult patients with spinal muscular atrophy improved during nusinersen treatment.
    Freigang M; Langner S; Hermann A; Günther R
    Muscle Nerve; 2023 Sep; 68(3):278-285. PubMed ID: 37466180
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.
    Gonski K; Chuang S; Teng A; Thambipillay G; Farrar MA; Menezes MP; Fitzgerald DA
    Neuromuscul Disord; 2023 Jun; 33(6):531-538. PubMed ID: 37290230
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
    Maggi L; Bello L; Bonanno S; Govoni A; Caponnetto C; Passamano L; Grandis M; Trojsi F; Cerri F; Ferraro M; Bozzoni V; Caumo L; Piras R; Tanel R; Saccani E; Meneri M; Vacchiano V; Ricci G; Soraru' G; D'Errico E; Tramacere I; Bortolani S; Pavesi G; Zanin R; Silvestrini M; Politano L; Schenone A; Previtali SC; Berardinelli A; Turri M; Verriello L; Coccia M; Mantegazza R; Liguori R; Filosto M; Marrosu G; Siciliano G; Simone IL; Mongini T; Comi G; Pegoraro E
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1166-1174. PubMed ID: 32917822
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy.
    Pera MC; Coratti G; Bovis F; Pane M; Pasternak A; Montes J; Sansone VA; Dunaway Young S; Duong T; Messina S; Mizzoni I; D'Amico A; Civitello M; Glanzman AM; Bruno C; Salmin F; Morando S; De Sanctis R; Sframeli M; Antonaci L; Frongia AL; Rohwer A; Scoto M; De Vivo DC; Darras BT; Day J; Martens W; Patanella KA; Bertini E; Muntoni F; Finkel R; Mercuri E;
    Ann Clin Transl Neurol; 2021 Aug; 8(8):1622-1634. PubMed ID: 34165911
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy.
    Kobayashi Y; Ishikawa N; Tateishi Y; Izumo H; Eto S; Eguchi Y; Okada S
    Brain Dev; 2023 Jan; 45(1):2-7. PubMed ID: 36210235
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen.
    Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C
    Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nutritional Therapy in Children With Spinal Muscular Atrophy in the Era of Nusinersen.
    Yerushalmy-Feler A; Levy D; Sagi L; Fattal-Valevski A; Shiff YE; Brener A; Cohen S
    J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):e154-e160. PubMed ID: 33492038
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neurofilament as a potential biomarker for spinal muscular atrophy.
    Darras BT; Crawford TO; Finkel RS; Mercuri E; De Vivo DC; Oskoui M; Tizzano EF; Ryan MM; Muntoni F; Zhao G; Staropoli J; McCampbell A; Petrillo M; Stebbins C; Fradette S; Farwell W; Sumner CJ
    Ann Clin Transl Neurol; 2019 May; 6(5):932-944. PubMed ID: 31139691
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance.
    Tachibana Y; Takasaki S; Hoshino M; Makioka H; Jin M
    Int J Neurosci; 2024 Jun; 134(2):153-162. PubMed ID: 35787224
    [No Abstract]   [Full Text] [Related]  

  • 79. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
    Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
    J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Dec; 29(12):3666-3675. PubMed ID: 36047967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.